Healthcare ransomware environment worsens, Beazley warns

In the first quarter of 2019, the number of ransomware attack notifications received by Beazley Breach Services doubled, compared with the same quarter last year. Not only has the frequency of attacks skyrocketed, but attackers are shifting focus by targeting larger organizations and demanding higher ransom payments. In 2015 and 2016, ransomware was a significant… Read More »

FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer

FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer Print this page May 24, 2019 — Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2… Read More »